Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

be incorporated into products that are sold; even if Senomyx or its collaborators receive a regulatory approval and incorporate Senomyx flavor ingredients into products, those products may never be commercially successful; Senomyx flavor ingredients may not be useful or cost-effective for formulation into products; Senomyx or its collaborators may be unable to manufacture Senomyx flavor ingredients at commercial scale; Senomyx's ability to compete in the flavor ingredients market may decline if Senomyx does not adequately protect its proprietary technologies; and Senomyx's discovery and development programs may not be successful or result in the discovery of new flavor ingredients that are commercially viable. These and other risks and uncertainties are described more fully in Senomyx's most recently filed SEC documents, including its most recent Annual Report on Form 10-K under the headings "Risks Related to Our Business" and "Risks Related to Our Industry." All forward-looking statements contained in this press release speak only as of the date on which they were made. Senomyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Financial Information to Follow)

 

Contacts:FinancialInvestor RelationsTony Rogers

Senior Vice President and

Chief Financial OfficerGwen Rosenberg

Vice President, Investor Relations &

Corporate CommunicationsSenomyx, Inc.Senomyx, Inc.858-646-8304858-646-8369tony.rogers@senomyx.comgwen.rosenberg@senomyx.com 

 

Selected Financial InformationCondensed Statements of Operations(in thousands, except for per share amounts) Three Months
Ended December 31,Year EndedDecember 31,2012201120122011(unaudited)(unaudited)Revenues:Development revenues$

6,734$<
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  Centrillion ... a SBIR grant from the National Human ... Institutes of Health (NIH). The grant will ... in the development of breakthrough genomic technologies, ... specially fabricated substrates. Centrillion has been developing ...
(Date:4/17/2015)... SYDNEY , April 17, 2015  US-Australian drug ... signed a Memorandum of Understanding with the Feinstein ... New York to collaborate with ... cancers. The collaboration brings together the ... and clinical expertise of the Feinstein Institute in ...
(Date:4/16/2015)... and OSAKA, Japan , ... Research Application (CiRA) of Kyoto University and Takeda ... will work together to develop clinical applications of ... heart failure, diabetes mellitus, neurological disorders and cancer ... Applications" (T-CiRA) is designed to expedite multiple research ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, ... technology, has signed a long-term lease on Laboratory Drive ... North Carolina . The location will house review ... to provide high quality reviews and customer service to ... represented Schulman in the deal, while Capital ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2
... FOLD ) today announced the election of ... Dr. Barer currently serves as Chairman and Chief ... veteran, Dr. Barer brings over 20 years of management ... leader who has helped transform Celgene into one of ...
... BURLINGTON, Mass., Jan. 8 Palomar Medical Technologies, ... researcher and developer of light-based systems for cosmetic ... distribution agreement with the Swedish company Q-MED AB ... biotech/medical device company based in Uppsala, Sweden. ...
... AMGN ) will present at the 27th Annual ... on Monday, Jan. 12, 2009, at the Westin St. Francis ... Sharer will present at the conference. Live audio of the ... accessed from Amgen,s Web site, www.amgen.com , under Investors. ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Palomar and Q-MED AB Terminate International Distribution Agreement 2Palomar and Q-MED AB Terminate International Distribution Agreement 3Palomar and Q-MED AB Terminate International Distribution Agreement 4Palomar and Q-MED AB Terminate International Distribution Agreement 5
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... of death in Europe and early diagnosis is essential ... electrical activity in real time using an electrocardiogram (ECG) ... the nature of a problem. Some cardiac conditions need ... them to be away from their everyday environment for ...
... Research engineers and sleep medicine specialists from two ... to put innovative quantitative analysis, signal-processing technology and ... One of their recent findings is that ... to distinguish fibromyalgia patients from healthy controls. ...
... given quercetin, a naturally occurring substance found in fruits ... according to a study published by The American Physiological ... the susceptibility of mice to the flu, but quercetin ... chemical relative of resveratrol, is present in a variety ...
Cached Biology News:A home early warning system for cardiac patients 2What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3Substance found in fruits and vegetables reduces likelihood of the flu 2Substance found in fruits and vegetables reduces likelihood of the flu 3
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
DNA fragmentation factor & Inhibitor of CAD...
Biology Products: